AT-03ATYPICAL TERATOID RHABDOID TUMORS IN THE FIRST YEAR OF LIFE: SHOULD WE TREAT?
Mary Fossey(University of British Columbia), Lucie Lafay‐Cousin(Women & Children's Hospital of Buffalo), Josée Brossard(Centre Hospitalier Universitaire de Sherbrooke), Haocheng Li(Roche (Canada)), Shayna Zelcer(London Health Sciences Centre), Annie Huang(Hospital for Sick Children), Adam Fleming(Montreal Children's Hospital), Donna L. Johnston(Children's Hospital of Eastern Ontario), Anne‐Sophie Carret(Montreal Neurological Institute and Hospital), David D. Eisenstat(Royal Children's Hospital), Éric Bouffet(Hospital for Sick Children), Cynthia Hawkins(Hospital for Sick Children), Nada Jabado(McGill University), Tanya Brown(Saskatchewan Cancer Agency), Valérie Larouche, Douglas Strother(Women & Children's Hospital of Buffalo), Chris Fryer(BC Children's Hospital), Beverly Wilson(University of Alberta), Katrin Scheinemann(University of Lucerne)
Cited by 0
Related Papers
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
|Acta Neuropathologica|2012|1k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867
Novel mutations target distinct subgroups of medulloblastoma
|Nature|2012|853
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795